glp-1 drugs and multiple sclerosis Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine Obesity medications linked to reduced

But does it balance cost and safety, or just look good on the surface

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

The search for over-the-counter GLP-1 alternatives reflects growing interest in weight loss support

This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.

This fact paved the way for the development of a GIP receptor agonist-based therapy for T2DM, looking also for the possibility of finding a combined GLP-1/GIP receptor agonist

Rheumatology insights & real results.